The detection of 3-methylglutarylcarnitine and a new dicarboxylic conjugate, 3-methylglutaconylcarnitine, in 3-methylglutaconic aciduria.

@article{Jooste1994TheDO,
  title={The detection of 3-methylglutarylcarnitine and a new dicarboxylic conjugate, 3-methylglutaconylcarnitine, in 3-methylglutaconic aciduria.},
  author={S V Jooste and E. Erasmus and L. J. Mienie and W. J. De Wet and Kenneth Michael Gibson},
  journal={Clinica chimica acta; international journal of clinical chemistry},
  year={1994},
  volume={230 1},
  pages={
          1-8
        }
}
  • S. Jooste, E. Erasmus, K. Gibson
  • Published 14 October 1994
  • Biology
  • Clinica chimica acta; international journal of clinical chemistry

Tables from this paper

Direct nonisotopic assay of 3-methylglutaconyl-CoA hydratase in cultured human skin fibroblasts to specifically identify patients with 3-methylglutaconic aciduria type I.
3-Methylglutaconic aciduria (3MGA) type I (McKusick 250950) is biochemically characterized by increased excretion of 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid in
3-Methylglutaconic aciduria type I redefined
TLDR
3-methylglutaconic aciduria type I is defined as an inborn error of metabolism with slowly progressive leukoencephalopathy clinically presenting in adulthood, and the clinical and neuroradiologic pattern in adult patients is highly characteristic.
3-Methylglutaconic Aciduria Type I Due to AUH Defect: The Case Report of a Diagnostic Odyssey and a Review of the Literature
TLDR
The case of a 31-month-old female child referred to the authors' center after the detection of increased 3-hydroxyisovalerylcarnitine levels at newborn screening and the presence of two microdeletions in compound heterozygosity encompassing the AUH gene, which confirmed the diagnosis of MGCA1, exemplifies the importance of the biochemical phenotype in the differential diagnosis of metabolic diseases.
Variable clinical presentation in three patients with 3-methylglutaconyl-coenzyme A hydratase deficiency
TLDR
3 patients with 3- MG-CoA hydratase deficiency who also manifested widely differing clinical presentations are presented, bringing to eight the total number of patients with documented 3-MG-Co A hydr atase deficiency.
3-Methylglutaconic aciduria, type 3
Mutations in the AUH gene cause 3‐methylglutaconic aciduria type I
TLDR
It is reported that human 3‐methylglutaconyl‐ CoA hydratase is identical with a previously described RNA‐binding protein (designated AUH) possessing enoyl‐CoA hyDRatase activity, which appears to be compatible with normal development in some cases.
Carnitine palmitoyltransferase I activity monitoring in fibroblasts and leukocytes using electrospray ionization mass spectrometry.
TLDR
An electrospray ionization mass spectrometric method for detectingPalmitoylcarnitine formation from palmitoyl-CoA and carnitine, thus avoiding the use of radiolabeled isotopes and making it an ideal technique to measure CPT I activity.
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
TLDR
An extensive review of acylcarnitines, including their nomenclature, structure and biochemistry, and use as disease biomarkers and pharmaceutical agents is provided, thereby providing a strong foundation for further clarification of their physiological roles.
Paracetamol prevents hyperglycinemia in vervet monkeys treated with valproate
TLDR
Results indicate that the γ-glutamyl cycle does indeed play a role in the hyperglycinemic effect of valproate treatment, and that paracetamol may have value in preventing and/or treatingValproate-induced NKH.
Structural elucidation of novel biomarkers of known metabolic disorders based on multistage fragmentation mass spectra
TLDR
This proof-of-concept study tests the applicability of current accurate mass multistage fragmentation techniques for structural elucidation of unknown metabolites in human biofluids, offering an unprecedented opportunity to gain further biochemical insights in known inborn errors of metabolism by enabling high confidence identification of novel biomarkers.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Deficiency of 3-methylglutaconyl-coenzyme A hydratase in two siblings with 3-methylglutaconic aciduria.
TLDR
A new assay for 3- methylglutaconyl-coenzyme A (CoA) hydratase has been developed in which the substrate was synthesized using 3-methylcrotonyl-CoA carboxylase purified from bovine kidney and the rates of conversion from substrate are measured.
Suberylglycine excretion in the urine from a patient with dicarboxylic aciduria.
Propionylcarnitine. Physiological variations in vivo.
Secondary carnitine insufficiency in disorders of organic acid metabolism: modulation of acyl-CoA/CoA ratios by l-carnitine in vivo
TLDR
This study presents a novel, scalable, scalable and scalable approach that allows for real-time evaluation of the impact of environmental factors on the B.C.R.S.A.
Carnitine deficiency, organic acidemias, and Reye's syndrome
TLDR
Relative carnitine deficiency is important in the pathophysiology of several disorders, including Reye's syndrome and organic acidemias, and Carnitine replacement therapy is safe and induces excretion of toxic acyl groups in the urine.
Secondary carnitine deficiency.
TLDR
It has been suggested that carnitine plays an important role in the intramitochondrial regulations of coenzyme A homeostasis by expelling short-chain and medium-chain acyl groups from the mitochondrion in the form of acylcarnitines.
Therapeutic Effects of Glycine in Isovaleric Acidemia
TLDR
The leucine loading tests and clinical response to oral glycine in this patient suggest that exogenously administered glycine enhanced the conjugation of glycine with isovaleryl-CoA, thus preventing accumulation of free isovaleric acid, a toxic substance.
...
...